Clinicians should consider long-term cognitive effects of anticholinergics, study says
A group of drugs that are prescribed for depression, Parkinson’s disease, urinary incontinence and other conditions have been linked to an increased risk of dementia.
The UK study, published this week in the British Medical Journal, found a ‘robust associations’ between some classes of anticholinergic drugs and future dementia incidence. As many as 40,770 patients aged 65 to 99 with a diagnosis of dementia between April 2006 and July 2015, and 283 933 controls without dementia, were included in the study.
Examples of anticholinergics, which block the action of the neurotransmitter acetylcholine, include Urispas (flavoxate) and Detrol (tolterodine), medications used to treat certain bladder/urinary tract symptoms and the Parkinson’s drugs Artane (trihexyphenidyl) and Cogentin (benzatropine).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze